APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Plasma-based Hyperimmune Preparation

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Plasma-based Hyperimmune Preparation Market Outlook and Growth Opportunities 2026

21 December 2025198 pages

Choose your research edition.

Industry ResearchHuman Plasma-based Hyperimmune Preparation Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Plasma-based Hyperimmune Preparation Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Human Plasma-based Hyperimmune Preparation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Plasma-based Hyperimmune Preparation Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Plasma-based Hyperimmune Preparation Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Human Plasma-based Hyperimmune Preparation market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Plasma-based Hyperimmune Preparation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Plasma-based Hyperimmune Preparation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Plasma-based Hyperimmune Preparation is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Plasma-based Hyperimmune Preparation market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Plasma-based Hyperimmune Preparation market include Sichuan Yuanda Shuyang, Shanghai RAAS, Grifols, Hualan Bio, Kedrion, Kamada, Emergent (Cangene), CSL Behring and CNBG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Human Plasma-based Hyperimmune Preparation market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Plasma-based Hyperimmune Preparation and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Plasma-based Hyperimmune Preparation sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Plasma-based Hyperimmune Preparation market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Plasma-based Hyperimmune Preparation Segment by Company

Sichuan Yuanda Shuyang

Shanghai RAAS

Grifols

Hualan Bio

Kedrion

Kamada

Emergent (Cangene)

CSL Behring

CNBG

CBPO

Biotest

ADMA Biologics

Human Plasma-based Hyperimmune Preparation Segment by Type

Hepatitis B Immunoglobulins

Tetanus Immunoglobulins

Rabies Immunoglobulins

Rho(D) Immunoglobulins

Other

Human Plasma-based Hyperimmune Preparation Segment by Application

Government Institution

Private Sector

Others

Human Plasma-based Hyperimmune Preparation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Plasma-based Hyperimmune Preparation status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Plasma-based Hyperimmune Preparation market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Plasma-based Hyperimmune Preparation significant trends, drivers, influence factors in global and regions.

6. To analyze Human Plasma-based Hyperimmune Preparation competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Plasma-based Hyperimmune Preparation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Plasma-based Hyperimmune Preparation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Plasma-based Hyperimmune Preparation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Plasma-based Hyperimmune Preparation market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Plasma-based Hyperimmune Preparation industry.

Chapter 3: Detailed analysis of Human Plasma-based Hyperimmune Preparation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Plasma-based Hyperimmune Preparation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Plasma-based Hyperimmune Preparation in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Plasma-based Hyperimmune Preparation Industry Trends Table 2. Human Plasma-based Hyperimmune Preparation Industry Drivers Table 3. Human Plasma-based Hyperimmune Preparation Industry Opportunities and Challenges Table 4. Human Plasma-based Hyperimmune Preparation Industry Restraints Table 5. Global Human Plasma-based Hyperimmune Preparation Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Plasma-based Hyperimmune Preparation Revenue Share by Company (2021-2026) Table 7. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Company (k units) & (2021-2026) Table 8. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Company (2021-2026) Table 9. Global Human Plasma-based Hyperimmune Preparation Average Price (US$/unit) of Company (2021-2026) Table 10. Global Human Plasma-based Hyperimmune Preparation Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Plasma-based Hyperimmune Preparation Key Company Manufacturing Base & Headquarters Table 12. Global Human Plasma-based Hyperimmune Preparation Company, Product Type & Application Table 13. Global Human Plasma-based Hyperimmune Preparation Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Plasma-based Hyperimmune Preparation by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hepatitis B Immunoglobulins Table 18. Significant Companies of Tetanus Immunoglobulins Table 19. Significant Companies of Rabies Immunoglobulins Table 20. Significant Companies of Rho(D) Immunoglobulins Table 21. Significant Companies of Other Table 22. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Type (2021-2026) & (k units) Table 24. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Type (2027-2032) & (k units) Table 25. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Type (2021-2026) Table 26. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Type (2027-2032) Table 27. Global Human Plasma-based Hyperimmune Preparation Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Human Plasma-based Hyperimmune Preparation Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Human Plasma-based Hyperimmune Preparation Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Type (2021-2026) Table 31. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Government Institution Table 33. Significant Companies of Private Sector Table 34. Significant Companies of Others Table 35. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Application (2021-2026) & (k units) Table 37. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Application (2027-2032) & (k units) Table 38. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Application (2021-2026) Table 39. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Application (2027-2032) Table 40. Global Human Plasma-based Hyperimmune Preparation Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Human Plasma-based Hyperimmune Preparation Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Human Plasma-based Hyperimmune Preparation Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Application (2021-2026) Table 44. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Application (2027-2032) Table 45. Global Human Plasma-based Hyperimmune Preparation Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Human Plasma-based Hyperimmune Preparation Sales by Region (2021-2026) & (k units) Table 47. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Region (2021-2026) Table 48. Global Human Plasma-based Hyperimmune Preparation Sales by Region (2027-2032) & (k units) Table 49. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Region (2027-2032) Table 50. Global Human Plasma-based Hyperimmune Preparation Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Human Plasma-based Hyperimmune Preparation Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Region (2021-2026) Table 53. Global Human Plasma-based Hyperimmune Preparation Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Region (2027-2032) Table 55. Global Human Plasma-based Hyperimmune Preparation Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Human Plasma-based Hyperimmune Preparation Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Human Plasma-based Hyperimmune Preparation Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Human Plasma-based Hyperimmune Preparation Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Human Plasma-based Hyperimmune Preparation Sales by Country (2021-2026) & (k units) Table 60. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2021-2026) Table 61. Global Human Plasma-based Hyperimmune Preparation Sales by Country (2027-2032) & (k units) Table 62. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Country (2027-2032) Table 63. Global Human Plasma-based Hyperimmune Preparation Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Human Plasma-based Hyperimmune Preparation Sales Value Market Share by Country (2021-2026) Table 65. Global Human Plasma-based Hyperimmune Preparation Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Human Plasma-based Hyperimmune Preparation Sales Value Market Share by Country (2027-2032) Table 67. Sichuan Yuanda Shuyang Company Information Table 68. Sichuan Yuanda Shuyang Business Overview Table 69. Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product Portfolio Table 71. Sichuan Yuanda Shuyang Recent Development Table 72. Shanghai RAAS Company Information Table 73. Shanghai RAAS Business Overview Table 74. Shanghai RAAS Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product Portfolio Table 76. Shanghai RAAS Recent Development Table 77. Grifols Company Information Table 78. Grifols Business Overview Table 79. Grifols Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Grifols Human Plasma-based Hyperimmune Preparation Product Portfolio Table 81. Grifols Recent Development Table 82. Hualan Bio Company Information Table 83. Hualan Bio Business Overview Table 84. Hualan Bio Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Hualan Bio Human Plasma-based Hyperimmune Preparation Product Portfolio Table 86. Hualan Bio Recent Development Table 87. Kedrion Company Information Table 88. Kedrion Business Overview Table 89. Kedrion Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Kedrion Human Plasma-based Hyperimmune Preparation Product Portfolio Table 91. Kedrion Recent Development Table 92. Kamada Company Information Table 93. Kamada Business Overview Table 94. Kamada Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Kamada Human Plasma-based Hyperimmune Preparation Product Portfolio Table 96. Kamada Recent Development Table 97. Emergent (Cangene) Company Information Table 98. Emergent (Cangene) Business Overview Table 99. Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product Portfolio Table 101. Emergent (Cangene) Recent Development Table 102. CSL Behring Company Information Table 103. CSL Behring Business Overview Table 104. CSL Behring Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. CSL Behring Human Plasma-based Hyperimmune Preparation Product Portfolio Table 106. CSL Behring Recent Development Table 107. CNBG Company Information Table 108. CNBG Business Overview Table 109. CNBG Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. CNBG Human Plasma-based Hyperimmune Preparation Product Portfolio Table 111. CNBG Recent Development Table 112. CBPO Company Information Table 113. CBPO Business Overview Table 114. CBPO Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. CBPO Human Plasma-based Hyperimmune Preparation Product Portfolio Table 116. CBPO Recent Development Table 117. Biotest Company Information Table 118. Biotest Business Overview Table 119. Biotest Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. Biotest Human Plasma-based Hyperimmune Preparation Product Portfolio Table 121. Biotest Recent Development Table 122. ADMA Biologics Company Information Table 123. ADMA Biologics Business Overview Table 124. ADMA Biologics Human Plasma-based Hyperimmune Preparation Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. ADMA Biologics Human Plasma-based Hyperimmune Preparation Product Portfolio Table 126. ADMA Biologics Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Human Plasma-based Hyperimmune Preparation Distributors List Table 130. Human Plasma-based Hyperimmune Preparation Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Human Plasma-based Hyperimmune Preparation Product Image Figure 2. Global Human Plasma-based Hyperimmune Preparation Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Plasma-based Hyperimmune Preparation Sales (2021-2032) & (k units) Figure 5. Global Human Plasma-based Hyperimmune Preparation Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Human Plasma-based Hyperimmune Preparation Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hepatitis B Immunoglobulins Image Figure 10. Tetanus Immunoglobulins Image Figure 11. Rabies Immunoglobulins Image Figure 12. Rho(D) Immunoglobulins Image Figure 13. Other Image Figure 14. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Type (2021-2032) Figure 17. Global Human Plasma-based Hyperimmune Preparation Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Human Plasma-based Hyperimmune Preparation Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Type (2021-2032) Figure 20. Government Institution Image Figure 21. Private Sector Image Figure 22. Others Image Figure 23. Global Human Plasma-based Hyperimmune Preparation Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Application (2021-2032) Figure 26. Global Human Plasma-based Hyperimmune Preparation Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Human Plasma-based Hyperimmune Preparation Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Application (2021-2032) Figure 29. Global Human Plasma-based Hyperimmune Preparation Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Human Plasma-based Hyperimmune Preparation Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Human Plasma-based Hyperimmune Preparation Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032) & (US$ Million) Figure 34. North America Human Plasma-based Hyperimmune Preparation Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Human Plasma-based Hyperimmune Preparation Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Human Plasma-based Hyperimmune Preparation Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032) & (US$ Million) Figure 40. South America Human Plasma-based Hyperimmune Preparation Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Human Plasma-based Hyperimmune Preparation Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Human Plasma-based Hyperimmune Preparation Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Hepatitis B Immunoglobulins
  • Tetanus Immunoglobulins
  • Rabies Immunoglobulins
  • Rho(D) Immunoglobulins
  • Other
Applications
  • Government Institution
  • Private Sector
  • Others
Companies covered
  • Sichuan Yuanda Shuyang
  • Shanghai RAAS
  • Grifols
  • Hualan Bio
  • Kedrion
  • Kamada
  • Emergent (Cangene)
  • CSL Behring
  • CNBG
  • CBPO
  • Biotest
  • ADMA Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032)
  4. 1.2.2 Global Human Plasma-based Hyperimmune Preparation Sales Volume (2021-2032)
  5. 1.2.3 Global Human Plasma-based Hyperimmune Preparation Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Plasma-based Hyperimmune Preparation Market Dynamics
  1. 2.1 Human Plasma-based Hyperimmune Preparation Industry Trends
  2. 2.2 Human Plasma-based Hyperimmune Preparation Industry Drivers
  3. 2.3 Human Plasma-based Hyperimmune Preparation Industry Opportunities and Challenges
  4. 2.4 Human Plasma-based Hyperimmune Preparation Industry Restraints
3 Human Plasma-based Hyperimmune Preparation Market by Company
  1. 3.1 Global Human Plasma-based Hyperimmune Preparation Company Revenue Ranking in 2025
  2. 3.2 Global Human Plasma-based Hyperimmune Preparation Revenue by Company (2021-2026)
  3. 3.3 Global Human Plasma-based Hyperimmune Preparation Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Plasma-based Hyperimmune Preparation Average Price by Company (2021-2026)
  5. 3.5 Global Human Plasma-based Hyperimmune Preparation Company Ranking (2024-2026)
  6. 3.6 Global Human Plasma-based Hyperimmune Preparation Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Plasma-based Hyperimmune Preparation Company Product Type and Application
  8. 3.8 Global Human Plasma-based Hyperimmune Preparation Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Plasma-based Hyperimmune Preparation Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Plasma-based Hyperimmune Preparation Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Plasma-based Hyperimmune Preparation Market by Type
  1. 4.1 Human Plasma-based Hyperimmune Preparation Type Introduction
  2. 4.1.1 Hepatitis B Immunoglobulins
  3. 4.1.2 Tetanus Immunoglobulins
  4. 4.1.3 Rabies Immunoglobulins
  5. 4.1.4 Rho(D) Immunoglobulins
  6. 4.1.5 Other
  7. 4.2 Global Human Plasma-based Hyperimmune Preparation Sales Volume by Type
  8. 4.2.1 Global Human Plasma-based Hyperimmune Preparation Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Human Plasma-based Hyperimmune Preparation Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Human Plasma-based Hyperimmune Preparation Sales Value by Type
  12. 4.3.1 Global Human Plasma-based Hyperimmune Preparation Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Human Plasma-based Hyperimmune Preparation Sales Value by Type (2021-2032)
  14. 4.3.3 Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Type (2021-2032)
5 Human Plasma-based Hyperimmune Preparation Market by Application
  1. 5.1 Human Plasma-based Hyperimmune Preparation Application Introduction
  2. 5.1.1 Government Institution
  3. 5.1.2 Private Sector
  4. 5.1.3 Others
  5. 5.2 Global Human Plasma-based Hyperimmune Preparation Sales Volume by Application
  6. 5.2.1 Global Human Plasma-based Hyperimmune Preparation Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Plasma-based Hyperimmune Preparation Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Human Plasma-based Hyperimmune Preparation Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Human Plasma-based Hyperimmune Preparation Sales Value by Application
  10. 5.3.1 Global Human Plasma-based Hyperimmune Preparation Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Human Plasma-based Hyperimmune Preparation Sales Value by Application (2021-2032)
  12. 5.3.3 Global Human Plasma-based Hyperimmune Preparation Sales Value Share by Application (2021-2032)
6 Human Plasma-based Hyperimmune Preparation Regional Sales and Value Analysis
  1. 6.1 Global Human Plasma-based Hyperimmune Preparation Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Plasma-based Hyperimmune Preparation Sales by Region (2021-2032)
  3. 6.2.1 Global Human Plasma-based Hyperimmune Preparation Sales by Region: 2021-2026
  4. 6.2.2 Global Human Plasma-based Hyperimmune Preparation Sales by Region (2027-2032)
  5. 6.3 Global Human Plasma-based Hyperimmune Preparation Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Plasma-based Hyperimmune Preparation Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Plasma-based Hyperimmune Preparation Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Plasma-based Hyperimmune Preparation Sales Value by Region (2027-2032)
  9. 6.5 Global Human Plasma-based Hyperimmune Preparation Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032)
  12. 6.6.2 North America Human Plasma-based Hyperimmune Preparation Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032)
  15. 6.7.2 Europe Human Plasma-based Hyperimmune Preparation Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Plasma-based Hyperimmune Preparation Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032)
  21. 6.9.2 South America Human Plasma-based Hyperimmune Preparation Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Plasma-based Hyperimmune Preparation Sales Value Share by Country, 2025 VS 2032
7 Human Plasma-based Hyperimmune Preparation Country-level Sales and Value Analysis
  1. 7.1 Global Human Plasma-based Hyperimmune Preparation Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Plasma-based Hyperimmune Preparation Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Plasma-based Hyperimmune Preparation Sales by Country (2021-2032)
  4. 7.3.1 Global Human Plasma-based Hyperimmune Preparation Sales by Country (2021-2026)
  5. 7.3.2 Global Human Plasma-based Hyperimmune Preparation Sales by Country (2027-2032)
  6. 7.4 Global Human Plasma-based Hyperimmune Preparation Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Plasma-based Hyperimmune Preparation Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Plasma-based Hyperimmune Preparation Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Plasma-based Hyperimmune Preparation Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Plasma-based Hyperimmune Preparation Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Plasma-based Hyperimmune Preparation Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sichuan Yuanda Shuyang
  2. 8.1.1 Sichuan Yuanda Shuyang Company Information
  3. 8.1.2 Sichuan Yuanda Shuyang Business Overview
  4. 8.1.3 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sichuan Yuanda Shuyang Human Plasma-based Hyperimmune Preparation Product Portfolio
  6. 8.1.5 Sichuan Yuanda Shuyang Recent Developments
  7. 8.2 Shanghai RAAS
  8. 8.2.1 Shanghai RAAS Company Information
  9. 8.2.2 Shanghai RAAS Business Overview
  10. 8.2.3 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shanghai RAAS Human Plasma-based Hyperimmune Preparation Product Portfolio
  12. 8.2.5 Shanghai RAAS Recent Developments
  13. 8.3 Grifols
  14. 8.3.1 Grifols Company Information
  15. 8.3.2 Grifols Business Overview
  16. 8.3.3 Grifols Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Grifols Human Plasma-based Hyperimmune Preparation Product Portfolio
  18. 8.3.5 Grifols Recent Developments
  19. 8.4 Hualan Bio
  20. 8.4.1 Hualan Bio Company Information
  21. 8.4.2 Hualan Bio Business Overview
  22. 8.4.3 Hualan Bio Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hualan Bio Human Plasma-based Hyperimmune Preparation Product Portfolio
  24. 8.4.5 Hualan Bio Recent Developments
  25. 8.5 Kedrion
  26. 8.5.1 Kedrion Company Information
  27. 8.5.2 Kedrion Business Overview
  28. 8.5.3 Kedrion Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kedrion Human Plasma-based Hyperimmune Preparation Product Portfolio
  30. 8.5.5 Kedrion Recent Developments
  31. 8.6 Kamada
  32. 8.6.1 Kamada Company Information
  33. 8.6.2 Kamada Business Overview
  34. 8.6.3 Kamada Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kamada Human Plasma-based Hyperimmune Preparation Product Portfolio
  36. 8.6.5 Kamada Recent Developments
  37. 8.7 Emergent (Cangene)
  38. 8.7.1 Emergent (Cangene) Company Information
  39. 8.7.2 Emergent (Cangene) Business Overview
  40. 8.7.3 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Emergent (Cangene) Human Plasma-based Hyperimmune Preparation Product Portfolio
  42. 8.7.5 Emergent (Cangene) Recent Developments
  43. 8.8 CSL Behring
  44. 8.8.1 CSL Behring Company Information
  45. 8.8.2 CSL Behring Business Overview
  46. 8.8.3 CSL Behring Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CSL Behring Human Plasma-based Hyperimmune Preparation Product Portfolio
  48. 8.8.5 CSL Behring Recent Developments
  49. 8.9 CNBG
  50. 8.9.1 CNBG Company Information
  51. 8.9.2 CNBG Business Overview
  52. 8.9.3 CNBG Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CNBG Human Plasma-based Hyperimmune Preparation Product Portfolio
  54. 8.9.5 CNBG Recent Developments
  55. 8.10 CBPO
  56. 8.10.1 CBPO Company Information
  57. 8.10.2 CBPO Business Overview
  58. 8.10.3 CBPO Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 CBPO Human Plasma-based Hyperimmune Preparation Product Portfolio
  60. 8.10.5 CBPO Recent Developments
  61. 8.11 Biotest
  62. 8.11.1 Biotest Company Information
  63. 8.11.2 Biotest Business Overview
  64. 8.11.3 Biotest Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Biotest Human Plasma-based Hyperimmune Preparation Product Portfolio
  66. 8.11.5 Biotest Recent Developments
  67. 8.12 ADMA Biologics
  68. 8.12.1 ADMA Biologics Company Information
  69. 8.12.2 ADMA Biologics Business Overview
  70. 8.12.3 ADMA Biologics Human Plasma-based Hyperimmune Preparation Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 ADMA Biologics Human Plasma-based Hyperimmune Preparation Product Portfolio
  72. 8.12.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Plasma-based Hyperimmune Preparation Value Chain Analysis
  2. 9.1.1 Human Plasma-based Hyperimmune Preparation Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Plasma-based Hyperimmune Preparation Sales Mode & Process
  6. 9.2 Human Plasma-based Hyperimmune Preparation Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Plasma-based Hyperimmune Preparation Distributors
  9. 9.2.3 Human Plasma-based Hyperimmune Preparation Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst